Abstract 606 Table 1

HERVs/LINEs expression associated with clinical outcomes, adjusted for sex, race and immunosuppressive medication use in 120 SLE participants. (FDR p<0.05)

HERVs/LINEs counts
CD4 CD14 CD19 NK
Up Down Up Down Up Down Up Down
Anti Sm antibody production 5 8 5 7 21 27 2 7
Disease severity(severe 2 cluster vs mild cluster) 2 15 4 10 1087 44 461 0
History of renal disease 1 4 2 1 5 12 0 0
Anti-RNP antibody production 6 7 4 8 17 9 1 0
Anti-dsDNA antibody production 35 2 5 2 21 11 0 0
Disease activity (SLEDAI score) 1 15 2 13 2 227 0 1
Congress, date, location Lupus 21st Century, September 20, 2022 – September 23, 2022, Loews Ventana Canyon Resort
Congress website https://web.cvent.com/event/a6cd0d72-4b4e-40a4-939b- c133c05df3af/summary
Abstract guidelines https://web.cvent.com/event/a6cd0d72-4b4e-40a4-939b- c133c05df3af/websitePage:795426fe-0fc9-44d7-9156-b30723c39052
Submission category • Genetics• Nucleic Acids in SLE• The Macrophage in SLE• Lupus Nephritis• Brain Injury in SLE• Pharmacoepidemiology• Clinical Research in SLE• Covid-19• Cutaneous SLE• SLE Diagnosis• Lupus-Targeted Therapeutics• Cardiovascular Disease and Lupus• PROs• Biomarkers in Clinical Trials• B Cells• Transcriptomics• T Cells• Innate Immunity• Autoantibodies• Microbiome
Presentation preference N/A
Character/word limit No limit stated, will ask congress to confirm
Figures/tables Allowed- No limit stated, will ask congressEmbed in abstract word doc
References N/A
Style
Other points A lay summary is required – see separate Lay summary file
Disclosures Not needed at submission
Other
Submission deadline August 1, 2022 at 11:59 PM ET